Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration

Author(s):  Dib Jean G, Abdulmohsin Saud

Issue:  Jan/Feb 2008 - Compounding for Hospice and Cancer Patients
View All Articles in Issue

Page(s):  8-14

Download in electronic PDF format for $65

Abstract:  Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, is used in the treatment of cancer. It was the first clinically available angiogenesis inhibitor in the U.S. Recently, bevacizumab has been used by ophthalmologists in the intravitreal treatment of choroidal neovascularization in agerelated macular degeneration. Since all published trials were less than one year in duration, including follow up, no conclusion can be drawn about the long-term safety and efficacy of intravitreal bevacizumab. In open-label studies, however, intravitreal bevacizumab has yielded marked improvements in visual acuity and central retinal thickness. Compounding pharmacists who are validated in aseptic compounding can prepare intravitreal bevacizumab from the available preservative-free phosphate-buffered intravenous solution using strict aseptic technique.

Related Keywords: Jean G. Dib, BSPharm, PharmD, MS, Saud Abdulmohsin, BSPharm, MS, formulations, bevacizumab, monoclonal antibody, vascular endothelial growth factor, VEGF, intravitreal administration, vitreous, eye, ophthalmic disorders, choroidal neovascularization, aging, macular degeneration, vision loss, visual acuity, retinal thickness, aseptic compounding, sterile preparation, blood vessels, angiogenesis, antiangiogenesis, drug costs

Related Categories: FORMULATIONS, GERIATRICS, OPHTHALMICS, DOSAGE FORMS/DRUG CARRIERS, PROFESSIONAL ISSUES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details)
Issue/​Page
View/Buy
Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
Dib Jean G
, Abdulmohsin Saud
Jan/Feb 2008
Pg. 8-14

Buy
Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration
Pereboom Marieke
, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J
Jan/Feb 2015
Pg. 70-72

Buy
Compounding with Biotechnology Products, Part 2: Product-specific Considerations
Allen Loyd V Jr
Nov/Dec 2022
Pg. 446-466

Buy
Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation
Robert Marie-Claude
, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Sep/Oct 2014
Pg. 418-426

Buy
Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops
Sahyoun Jean-Yves
, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Jul/Aug 2022
Pg. 336-341

Buy
Infliximab 1% Ophthalmic Solution
Allen Loyd V Jr
Jan/Feb 2017
Pg. 62

Buy
Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis
Mixon William
, Angelle Patricea (Patsy), Chang Richard I
Nov/Dec 2009
Pg. 506-515

Buy
The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women
Stephenson Kenna
, Neuenschwander Pierre F, Kurdowska Anna K
Jan/Feb 2013
Pg. 74-85

View Sample
The History of Pluronic Lecithin Organogel: An Interview With Marty Jones, BSPharm, FACA, FIACP
Allen Loyd V Jr
May/Jun 2003
Pg. 180-183

Buy
I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease
McElhiney Linda F
May/Jun 2012
Pg. 190-195

Buy
Particle Measuring Systems - USP <797> Environmental Monitoring Solutions